Home » Stocks » Bicycle Therapeutics

Bicycle Therapeutics PLC (BCYC)

Stock Price: $16.01 USD -0.31 (-1.90%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 289.65M
Revenue (ttm) 8.60M
Net Income (ttm) -37.33M
Shares Out 19.28M
EPS (ttm) -4.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $16.01
Previous Close $16.32
Change ($) -0.31
Change (%) -1.90%
Day's Open 16.20
Day's Range 15.50 - 16.94
Day's Volume 12,725
52-Week Range 6.24 - 20.10

More Stats

Market Cap 289.65M
Enterprise Value 193.59M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.28M
Float 2.89M
EPS (basic) -1.6
EPS (diluted) -4.99
FCF / Share -0.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 100,747
Short Ratio 1.41
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 33.70
PB Ratio 4.43
Revenue 8.60M
Operating Income -39.24M
Net Income -37.33M
Free Cash Flow -8.29M
Net Cash 96.06M
Net Cash / Share 5.31
Gross Margin -136.58%
Operating Margin -456.58%
Profit Margin -434.30%
FCF Margin -96.40%
ROA -20.03%
ROE -42.52%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(47.66% upside)
Current: $16.01
Target: 23.64
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth93.4%246.41%-
Gross Profit13.807.142.06
Operating Income-26.30-21.75-16.21
Net Income-30.61-21.85-16.26
Shares Outstanding11.050.440.33
Earnings Per Share-2.77-49.78-48.81
Operating Cash Flow-28.61-26.08-1.42
Capital Expenditures-1.56-1.19-1.11
Free Cash Flow-30.17-27.26-2.53
Cash & Equivalents92.1263.3867.66
Total Debt1.25--
Net Cash / Debt90.8763.3867.66
Book Value93.20-69.83-47.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Bicycle Therapeutics PLC
Country United Kingdom
Employees 72
CEO Kevin Lee

Stock Information

Ticker Symbol BCYC
Stock Exchange NASDAQ
Unique Identifier NASDAQ: BCYC
IPO Date May 23, 2019


Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. Bicycle Therapeutics plc has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.